article thumbnail

CMS Proposes New Services for Vulnerable Patients: Reimbursement for Community Health Integration, Social Determinants Risk Assessment, and Principal Illness Navigation

Nixon Gwilt Law

healthcare system is access to equitable care for our most vulnerable patient populations. Rethinking Healthcare: Addressing Social Determinants in Patient Treatment Practitioners and their staff often dedicate valuable time and resources to understanding the social determinants that may impact their ability to successfully treat a patient.

article thumbnail

When it comes to telehealth it’s not numbers

World of DTC Marketing

Still, they are more likely to continue use because of complex medical conditions or a nonclinical factor such as lack of transportation” OK, so where to start…First, let’s ask a fundamental question “why are people using telehealth? 83% believed the quality of the patient-physician communication was good.

Doctors 247
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Lexicon gets FDA approval for Inpefa to treat heart failure

Pharmaceutical Technology

Inpefa is a once-daily oral tablet indicated as an inhibitor of sodium-glucose co-transporter type 2 (SGLT2) and type 1 (SGLT1). The approval for Inpefa was based on data from two double-blind, placebo-controlled and randomised Phase III cardiovascular outcomes trials in patients with heart failure or who are at risk of heart failure.

article thumbnail

The power of patterns: patient journeys, data analytics and the quest for a better healthcare system

Clarify Health

Leveraging Data to Improve Patient Journeys Healthcare Unbound episode recap: There’s never been more healthcare data (or access to it). Data on various aspects of patients’ journeys through the healthcare system are particularly powerful for both providers and payers. “But they have evolved over time.”

article thumbnail

From trial design for patients to trial design with patients: a key topic at DIA ’22

pharmaphorum

At the 2022 Drug Information Association (DIA) annual meeting last week, it was inspiring to connect with fellow research and development (R&D) stakeholders, regulators, health and digital data partners and more to navigate challenges in drug development that impact patients globally. Patient journey. Patient access.

article thumbnail

Sourcing Insights from People Not Like Me

PM360

Meanwhile the life sciences market research trade association, Intellus, noted that market insights participants are often white, female, and upper middle income, even when healthcare professional (HCP) prescribers and patients encompass a wide range of backgrounds. Ensure accessible locations, transportation, and time of day if in person.

article thumbnail

How one pharma “family business” places patients first

pharmaphorum

And just as a family business thrives on its connection to the community, Chiesi is committed to connecting to the global patient community. We try to have a very long-term orientation because we believe that aligns our objectives very well with the objectives of society and the patients we serve, and it makes us a stable business.”.